LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
LENZ Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$3.30+0.03 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $103.54M
- P/E (TTM)
- –
- Dividend yield
- –
LENZ Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| License revenue | $17.50M | $0 | – | 91.7% | – |
| Product sales, net | $1.59M | $0 | – | 8.3% | – |
By region
From the segment and revenue-disaggregation notes of LENZ Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.